You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Combination Immunotherapy of a Novel Superagonist IL-15 Complex and Anti-CD20 Antibody for Indolent Non-Hodgkin Lymphoma

    SBC: Altor BioScience, LLC            Topic: 102

    DESCRIPTION provided by applicant Non Hodgkin lymphoma NHL is the most commonly diagnosed hematologic malignancy in the U S with over new cases and about deaths due to NHL expected in Over one third of all cases are slow growing or indolent NHL iNHL which affect older adults and typically present as advanced disease The initial treatment of iNHL consists of an anti CD ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Therapeutic Neutralization of the Inflammasome After Spinal Cord Injury

    SBC: INFLAMACORE LIMITED LIABILITY COMPANY            Topic: 105

    DESCRIPTION provided by applicant Spinal cord injury SCI is a complex and devastating clinical condition mediated by proinflammatory cytokines that produce neuronal loss axonal destruction and demyelination during the secondary injury cascade There are currently no proven therapies targeting posttraumatic inflammation that have been shown to have clinical value We have previously shown th ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Novel selective alpha4beta2 nicotinic receptor antagonists for smoking cessation

    SBC: ASSUAGE PHARMACEUTICALS, INC.            Topic: NIDA

    DESCRIPTION provided by applicant Smoking remains the number one avoidable cause of death in the United States and costs the economy tens of billions of dollars every year Current therapies include nicotine replacement with a patch or gum inhibition of the dopamine system with bupropion and partial activation of the neuronal nicotinic acetylcholine receptor nAChR with varenicline Non ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. External GFP fusion enables FRET based binding for addiction related receptors

    SBC: BRILLIANT BIOSCIENCES INC.            Topic: R43

    DESCRIPTION provided by applicant The rise in popularity of fluorescent based assays have in addition to the increased environmental restrictions on radioactive materials have led to a parallel decline in the availability of radioactive ligands and the associated equipment for receptor binding assays Although there is an abundance of fluorescent based functional assays for G coupled protei ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. eClinic: An Innovative Technology for Clinical Laboratory Sciences Education

    SBC: The Athena Group, Inc.            Topic: 100

    DESCRIPTION provided by applicant The Athena Group Inc Athena in close collaboration with practicing faculty and clinicians at Morgan State University MSU University of Delaware UD and George Washington University GWU proposes the Phase II development of eClinic as an effective affordable and sustainable educational software product de signed to improve the quality of the under ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Generation of hairless rat pain models

    SBC: VELOCITY LABORATORIES, LLC            Topic: 300

    DESCRIPTION provided by applicant Pain is the most common reason for individuals to seek medical care This epidemic leads to the expenditure of billions of dollars for prescription and over the counter analgesics and alternative therapies Several hundred billion more dollars are spent due to lost productivity as a result of pain In a recent report the Institute of Medicin recommended that re ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Low-Cost Catalytic Biomass Cookstove for Improved Indoor Air Quality

    SBC: MAINSTREAM ENGINEERING CORP            Topic: NIEHS

    DESCRIPTION provided by applicant An estimated billion people or about one third of the worldandapos s population rely on biomass fuel for cooking Emissions from biomass cookstoves contribute to global climate change indoor local air quality issues and related health effects I particular indoor air quality issues related to biomass cookstoves contribute significantly to rates of acut ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Receptors, Ligands, and Catalysts on Demand using Expanded Genetic Alphabets

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: 100

    DESCRIPTION provided by applicant Technology to deliver molecules andquot on demandandquot that bind to targets or catalyze reactions of a technologistandapos s choosing would have enormous commercial value in research manufacturing and medicine Thus this has been a andquot holy grailandquot of molecular science for a half century Even today chemical theory is inadequate to support de ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. A Fully Independent Real Time Treatment Verification System for Radiotherapy

    SBC: SUN NUCLEAR CORP.            Topic: 102

    DESCRIPTION provided by applicant Modern day radiotherapy has developed in complexity to the degree that significant treatment errors are both difficult to detect and difficut to completely avoid In the current day radiotherapy department it is common to have a large number of patients being treated with Intensity Modulated Radiotherapy IMRT techniques When treating patients with these tec ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting CD137L to MC1R-Expressing Melanoma Cells and Tumors.

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    DESCRIPTION provided by applicant There are specific high affinity ligands for receptors found on many cancers that have been investigated as imaging probes and we believe that we should try to enhance immunotherapy by using these ligands to deliver immune effectors to the cancer microenvironment Melanoma is among the most immunogenic tumors known and so that disease is an excellent test bed f ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government